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Introduction
Hypercalcemia is associated with a variety of endocrine
and metabolic diseases (Table 1), hyperparathyroidism
and cancer being the two most common causes [1].
Patients presenting with asymptomatic hypercalcemia
or chronic symptoms are most commonly affected by
primary hyperparathyroidism, while on the other hand,
patients with symptomatic hypercalcemia and weight
loss of recent onset are more likely to suffer from an
underlying malignant disorder. In general, the presence
of an elevated serum calcium with a low or normal
serum parathyroid hormone (PTH), especially when
combined with an increase in serum parathyroid hor-
mone-related protein (PTH-rP) is sufficient to exclude
the diagnosis of primary hyperparathyroidism [2, 3].
Hypercalcemic patients may complain of a variety of
symptoms affecting several systems. The most frequent
clinical manifestations of cancer related hypercalcemia
are: dehydration, weight loss, anorexia, pruritus, poly-
dipsia, neuromuscular symptoms (fatigue, lethargy,



















muscle weakness, confusion, psychosis, coma), gastro-
intestinal problems (nausea, vomiting, constipation,
ileus), urogenital (polyuria, renal insufficiency) and car-
diac (bradycardia, wide T wave, atrial or ventricular
arrhythmia) abnormalities.
Hypercalcemia is the most common life threatening
metabolic disorder in patients with cancer: overall, it
owns in about 5%-10% of cancer but it is most common
in patients with squamous cell cancer of the lung, breast
cancer, multiple myeloma, uroepithelial cancer, lym-
phoma and leukaemia.
The classic, mechanistic explanation that hypercalce-
mia was the result of direct tumour-induced bone re-
sorption has been abandoned in favour of multiple,
different pathogenic mechanisms which may be specfic
for different tumour types.
Theoretically, three major mechanisms can be re-
sponsible for hypercalcemia:
1. increased calcium release from bone;
2. reduced renal calcium excretion;
3. excessive intestinal calcium absorption.
In tumour-induced hypercalcemia, chemical mediators
produced by cancer cells increase bone resorption and
impair calcium excretion by directly affecting renal tub-
ular excretion (Figure 1).
Bone resorption may also be induced by TGF (trans-
forming growth factor), TNF (tumour necrosis factor),
IL-1, prostaglandins and other tumour factors [4].
Intestinal calcium absorption may be increased by
vitamin D3.
PTH-rP, which is secreted by some tumour cells,
enhances both tubular reabsorption and bone calcium
resorption [4].
Case report
A 69-year-old woman with metastatic breast cancer had
undergone a left radical mastectomy in April 1989 for
invasive ductal carcinoma (pT3, pN+[2/14], M0) with
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Figure I. Pathogenesis of malignancy-associated hypercalcemia. Modi-
fied from H. Ludwing and E. Fritz, Oncological emergencies, Textbook
of Medical Oncology (1997).
oestrogen receptor status positive. Adjuvant tamoxifen
(20 mg daily) was given until 1994. In August 1997 the
patient developed a left malignant pleural effusion and
was treated by drainage and insufflation of sterilised
talcum powder by thorascopy: at that time radiological
screening for bone desease showed osteolytic metastatic
involvement of the IX left rib only, her liver ultrasound
was normal. Treatment with tamoxifen and bisphospho-
nates was started. In January 1998 the patient under-
went surgical excision of a local recurrence on the left
chest wall.
In February 1998 she presented with diarrhoea and
hypercalcemia (Ca++ 3.3 mmol/1 with normal values
ranging from 2.10-2.70 mmol/1): alkaline phosphatase
was 104 U/l (normal 31-108 U/l) and creatinine was
within normal values. These results were judged as signs
of biological activity of her breast cancer and a new
hormonal treatment with letrozol was started without
any improvement. Two months later the patient became
somnolent and poorly oriented, her calcium was still
3.12 mmol/1, creatinine was raised to 83 micromol/1
(normal 44-80 micromol/1), PTH and urinary c AMP
were slightly below normal values and VitD3 was normal.
These findings supported the hypothesis of a paraneo-
plastic syndrome which was confirmed by an increased
level of serum PTH-rP (16.2 pmol/1 with normal level
<2 pmol/1). The hypercalcemia did not respond to
bisphosphonates, hyperhydration with isotonic saline,
diuretics (furosemide 40 mg e.v.), or prednisone (50 mg/
daily, orally). Calcitonin (600 U/24 hours) was then
added, with no apparent benefit. Letrozol was interrupted
and chemotherapy with mitoxantrone (20 mg total) was
initiated. After a few days she became more somnolent
and developed polydipsia with serum calcium raising
to 5.2 mmol/1 and creatinine tol35 micromol/1. Haemo-
dialysis was immediately started with progressive de-
crease in the serum calcium levels, which returned within
normal ranges in a few days, and slow improvement of
patient's consciousness. One month later the patient be-

















Figure 2. Treatment of patient's hypercalcemia.
to 3.63 micromol/1, creatinine was slightly increased
(111 micromol/1) in presence of unchanged radiological
images (ribs X-ray and bone scan). Low dose weekly
doxorubicin (20 mg total) together with continuous
infusion 5-fluorouracil (5-FU, 300 mg e.v./daily) was
started. Gradually her neurological condition improved
and the calcium level decreased and stabilised for a few
months. In September 1998 she developed grade 4 diar-
rhoea and became somnolent, with a new increase in
serum calcium (3.12 mmol/1) and creatinine (138 micro-
mol/1), the serum PTH-rP level was again 16.3 pmol/1.
Treatment with weekly docetaxel (60 mg total) was
started with good control of hypercalcemia until today
(Figure 2).
Discussion
Hypercalcemia is the most frequent metabolic compli-
cation of breast cancer and it has usually been attributed
to skeletal metastases with local osteolysis by tumour-
derived factors.
Hovever, this metabolic disorder can be also related
to the effect of tumour-derived parathyroid hormone-
like factors both on kidney and bone and the current
hypothesis is that the pathogenesis of hypercalcemia in
breast cancer is mediated humorally through PTH-rP.
PTH-rP is secreted by some tumours cells and it is
supposed to mediate malignant hypercalcemia by bind-
ing to the parathyroid hormone related peptide receptor
and then stimulating osteoclastic bone resorption and
renal tubular calcium reabsorption. Its role as a humoral
factor in malignant hypercalcemia has been recently
established by several authors [5, 6]: elevated serum
PTH-rP levels have been found in 30%-50% of hyper-
calcemic patient with breast cancer, even though hyper-
calcemia was concomitant with bone metastases, and its
concentrations were significantly higher in hypercalcemic
than in normocalcemic patients with bone metastases [7].
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In breast carcinoma with metastatic bone spread
PTH-rP is elevated in 90% of cases, as compared with
only 17% of cases with non-skeletal metastases. These
observations have led to the hypothesis that PTH-rP
might contribute to the growth of breast cancer cells in
bone due to its ability to stimulate osteoclastic bone
resorption [8]: experimental evidence is currently avail-
able to support this hypothesis [9].
Other growth factors, such as TGF-beta, which are
abundant in the bone matrix, are released and activated
by osteoclastic bone resorption and may enhance PTH-rP
expression and tumour cell growth [8].
Other in vivo studies have demonstrated that local
production of PTH-rP by breast cancer cells can cause
bone destruction, even in the absence of hypercalcemia
or increased circulating plasma concentrations of
PTH-rP [10]. Neutralising antibodies to PTH-rP may
reduce the development of destructive bone lesions as
well as the growth of tumour cells in bone [10].
From the clinical perspective, very few controlled
studies have addressed the issue of the optimal treatment
of cancer-related hypercalcemia. Interpretation of clin-
ical trial results is confounded by enormous variability
in patient selection, underlying diagnoses, severity of
hypercalcemia and by unique methods of reporting
results [11].
The best treatment for cancer-related hypercalcemia
should be directed at the underlying disease but hyper-
calcemia most commonly occurs in patients with ad-
vanced disease in whom cytotoxic therapy has failed.
The usual therapies for hypercalcemia aim at decreasing
serum calcium by increasing urinary excretion or de-
creasing bone resorption by inhibition of osteoclastic
function.
Treatment with vigorous intravenous saline hydration
(3000-6000 ml daily) represented the historical approach
to hypercalcemia through restoration of the extracellular
fluid deficit and induction of calcium diuresis. This
procedure may reduce calcium levels by 0.3-0.5 mmol
over the first 48 hours by itself, but most patients need
additional combination with high doses of loop diuretics
(furosemide 80-100 mg/day) to induce a sodium-linked
calcium diuresis. This therapy can be excessively toxic as
it frequently causes fluid overload and occasionally life-
threatening pulmonary oedema [12].
In recent years hydration with isotonic saline, with or
without diuretics, and bisphosphonates have been estab-
lished as standard treatment of cancer associated hyper-
calcemia [12]. Bisphosphonates are chemical analogues
of pyrophosphate that adsorb to the surface of crystal-
line hydroxyapatite and inhibits calcium release from
bone by interfering with the metabolic activity of osteo-
clasts [13]. Three the bisphosphonates are currently
available: etidronate, pamidronate and clodronate. Of
these, pamidronate is probably the most potent and has
become the most widely prescribed drug for the treat-
ment of hypercalcemia [14]. A single-dose, (60-90 mg
over two to four hours) has been reported to induce
normalisation of serum calcium concentration in 70%-
100% of treated patients [14, 15]. Pamidronate binds to
bone and reduces resorption, but has no effect on the
renal tubule [16]: patients with cancer-related hyper-
calcemia who have a detectable renal component have
therefore usually a poor response to bisphosphonates [17].
An Australian report of 44 patients with tumour-
induced hypercalcemia suggested that a poor response
to bisphosphonates could be due to high concentrations
of PTH-rP. PTH-rP was the best predictor for response,
with high PTH-rP levels inversely correlating with re-
sponse [16]. In poor response patients a post-treatment
calcium clearance estimation showed that pamidronate
effectively inhibited bone resorption but did not correct
the tubular defect. This implies that the failure to inhibit
the renal mechanism of hypercalcemia is probably the
main cause of a poor response.
The development of drugs that inhibit tubular reab-
sorption of calcium [18], specifically inhibit PTH or
PTH-rP action [19], or PTH-rP secretion or new anti-
bodies against PTH-rP [20], could provide a better con-
trol of hypercalcemia in these patients when used in
combination with the available inhibitors of osteolysis.
Other treatment options for hypercalcemia are calci-
tonin, corticosteroids, intravenous phosphate infusion,
mithramicycin, gallium nitrate and prostaglandin inhib-
itors.
Calcitonin is the most useful drug; it effectively
inhibits osteoclastic bone resorption as well as renal
tubular calcium reabsorption and can lower serum cal-
cium levels within two hours after treatment [21]. Calci-
tonin's effect on bone resorption is transient because of
down regulation of receptors on osteoclasts, but it has a
more sustained influence on the renal tubular calcium
excretion, which accounts for its ability to control hyper-
calcemia for long periods of time. A recent Japanese
study combined the rapid hypocalcemic effect of calci-
tonin together with the delayed effect of pamidronate in
five patients with malignant hypercalcemia: no toxicity
was reported and the combination allowed a rapid, long
term control of hypercalcemia, possibly representing the
treatment of choice in severe hypercalcemia [22].
Treatment with corticosteroids in patients with hyper-
calcemia and solid tumours has been disappointing [23].
Nevertheless, a recent randomised study performed in
patients with metastatic breast cancer showed some
beneficial effect [24]. The fact that response to cortico-
steroids may be observed after at least one week or more
makes it imperative that more effective and rapid means
of lowering serum calcium levels be used in sympto-
matic patients.
Intravenous phosphate infusion, mithramycin, gallium
nitrate and prostaglandin inhibitors have significant dis-
advantages. Intravenous phosphate infusion may lead to
renal precipitation of calcium-phosphate complexes and
subsequent acute renal failure [25]. Mitramycin, a po-
tent osteoclast inhibitor, may be associated with serious
toxicity: thrombocytopenia, hepatic dysfunction, renal
tubular damage and gastrointestinal side effects [26].
Gallium nitrate has been successfully used for treatment
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of cancer associated hypercalcemia but its drawback lies
in the requirement for a continuous intravenous infusion
over five days [27]. Inhibitors of prostaglandin synthesis
are effective only in an unpredictable 5% of patients with
cancer related hypercalcemia [28].
Conclusions
The present case underlines the potential importance of
PTH-rP as cause of severe, refractory hypercalcemia in
patients with metastatic breast cancer. Its determina-
tion, whenever possible, can add useful information and
lead to a better and more rational treatment strategy.
Hydration with diuretics and bisphosphonates are the
first steps in the management of hypercalcemia but
chemotherapy seems to be the fundamental tool in the
long-term control of this paraneoplastic syndrome. The
addition of calcitonin and corticosteroids can contribute
to the optimal control of hypercalcemia but their specific
role in the management of this patient cannot be clearly
established.
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